← Browse by Condition
Medical Condition

hypertrophic cardiomyopathy

Total Trials
3
Recruiting Now
3
Trial Phases
Various

ClinicalMetric tracks all active clinical trials for hypertrophic cardiomyopathy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hypertrophic cardiomyopathy Clinical Trials

How many clinical trials are currently recruiting for hypertrophic cardiomyopathy?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for hypertrophic cardiomyopathy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hypertrophic cardiomyopathy?
hypertrophic cardiomyopathy research spans multiple clinical trial phases. Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hypertrophic cardiomyopathy clinical trial?
Eligibility criteria for hypertrophic cardiomyopathy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Magdi Yacoub Heart Foundation 1 trial
Wuerzburg University Hospital 1 trial
University of Edinburgh 1 trial

Recruiting Clinical Trials

NCT05884892
Recruiting
Egyptian Hypertrophic Cardiomyopathy Program
Enrollment
2,000 pts
Location
Egypt
Sponsor
Magdi Yacoub Heart Foundation
View Trial →
NCT03362164
Recruiting
Evaluation of HEArt invoLvement in Patients With FABRY Disease
Enrollment
650 pts
Location
Germany
Sponsor
Wuerzburg University Hospital
View Trial →
NCT06409585
Recruiting
Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
Enrollment
290 pts
Location
United Kingdom
Sponsor
University of Edinburgh
View Trial →

Related Conditions

rare diseases (1) fabry disease (1) fabry disease cardiac variant (1) heart failure with preserved ejection fraction (1) cardiac sarcoidosis (1) hypertensive heart disease (1) tako tsubo cardiomyopathy (1) arrhythmogenic right ventricular cardiomyopathy 1 (1) myocarditis (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology